

CERTIFICATE OF ANALYSIS No.: 2026-19046

CLIENT

USA MEDICAL KORLÁTOLT FELELŐSSÉGŰ
TÁRSASÁG, Alkotás u. 53/A
1123 Budapest, Hungary



SAMPLE *

USA medical 1000 mg CBD oil

Sample condition: SUITABLE
Sample ID: 2637040
Sample type: Viscous liquid
Batch No.: * NKS102606-04

Work order: 2026-113542
Analysis ID: 2026_277
Method ID: PHL_RPC_16C
Method SOP: MET-LAB-001-08

Sample received: 11/09/2026
Start of analysis: 15/09/2026
End of analysis: 23/09/2026
Analyst: Jhansi L.K. Mamilla

* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	< LOQ	n/a	
CBDA	- Cannabidiolic acid	< LOQ	n/a	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	< LOQ	n/a	
CBD	- Cannabidiol	3.74	0.19	
THCV	- Tetrahydrocannabivarin	< LOQ	n/a	
CBN	- Cannabinol	< LOQ	n/a	
Δ⁹-THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
Δ⁸-THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ⁹-THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	< LOQ	n/a	
CBCA	- Cannabichromenic acid	< LOQ	n/a	
CBT	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	< LOQ	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.


The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:


23/09/2026

Approved by:



mag. Valentina Malin
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar
Chief Technology Officer

End of Certificate